Cargando…
Serum proteomics in giant cell arteritis in response to a three-day pulse of glucocorticoid followed by tocilizumab monotherapy (the GUSTO trial)
OBJECTIVE: Proteome analyses in patients with newly diagnosed, untreated giant cell arteritis (GCA) have not been reported previously, nor are changes of protein expression upon treatment with glucocorticoids (GC) and/or tocilizumab (TCZ) known. The GUSTO trial allows to address these questions, pro...
Autores principales: | Christ, Lisa, Gloor, Andrea D., Kollert, Florian, Gaber, Timo, Buttgereit, Frank, Reichenbach, Stephan, Villiger, Peter M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242646/ https://www.ncbi.nlm.nih.gov/pubmed/37287970 http://dx.doi.org/10.3389/fimmu.2023.1165758 |
Ejemplares similares
-
Vision loss in patients with giant cell arteritis treated with tocilizumab
por: Amsler, Jennifer, et al.
Publicado: (2021) -
Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis
por: Seitz, Luca, et al.
Publicado: (2021) -
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study
por: Schmitt, Christophe, et al.
Publicado: (2022) -
Stratified glucocorticoid monotherapy is safe and effective for most cases of giant cell arteritis
por: Karabayas, Maira, et al.
Publicado: (2020) -
Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)